Celldex Therapeutics (CLDX) Net Margin (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Net Margin of 572686.67% for Q1 2026, down 56494624.0% year-over-year from N/an in Q1 2025, and down 532.14% quarter-over-quarter from 90594.21% in Q4 2025.
Powered by 
Analysis
Celldex Therapeutics (CLDX) Net Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 572686.67% for Q1 2026.
- In Q1 2026, Net Margin fell 56494624.0% year-over-year to 572686.67%; the TTM figure through Mar 2026 stood at 37733.6% (down 3536705.0% YoY), while the FY2025 annual figure was 42819.42%, down 4057013.0% from the prior year.
- Net Margin for Q1 2026 stood at 572686.67%, down from 90594.21% in the prior quarter.
- The five-year high for Net Margin was 1048.32% in Q4 2023, with the low at 572686.67% in Q1 2026.
- The 5-year median for Net Margin is 7160.63% (2022), against an average of 48072.46%.
- The sharpest annual moves came in 2025 and 2026: Net Margin soared 1329034 bps in 2025, then tumbled 56494624 bps in 2026.
- Celldex Therapeutics' Net Margin stood at 1642.1% in 2022, then jumped by 36 bps to 1048.32% in 2023, then plunged by 283 bps to 4010.98% in 2024, then plunged by 2159 bps to 90594.21% in 2025, then slumped by 532 bps to 572686.67% in 2026.
- Business Quant data shows CLDX's Net Margin at 572686.67% in Q1 2026, 90594.21% in Q4 2025, and 8795.07% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Celldex Therapeutics | 3.10 Bn | 3.10 Bn | -2.57 Mn | -334,104.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -334,104.55% |
| Mar 31, 2026 | -570,260.00% |
| Dec 31, 2025 | -67,204.13% |
| Jun 30, 2025 | -7,753.42% |
| Mar 31, 2025 | -7,741.01% |
| Dec 31, 2024 | -4,008.51% |
| Sep 30, 2024 | -1,319.99% |
| Jun 30, 2024 | -1,434.83% |
| Mar 31, 2024 | -21,030.77% |
| Dec 31, 2023 | -1,048.32% |
| Sep 30, 2023 | -2,522.08% |
| Jun 30, 2023 | -11,381.34% |
| Mar 31, 2023 | -3,036.30% |
| Dec 31, 2022 | -1,642.10% |
| Sep 30, 2022 | -6,580.84% |
| Jun 30, 2022 | -22,088.34% |
| Mar 31, 2022 | -13,247.13% |
| Dec 31, 2021 | -6,032.34% |
| Sep 30, 2021 | -13,367.32% |
| Jun 30, 2021 | -384.28% |